NCT01416896

Brief Summary

Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Aug 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

August 9, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 15, 2011

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

August 15, 2011

Status Verified

August 1, 2011

Enrollment Period

1.1 years

First QC Date

August 9, 2011

Last Update Submit

August 12, 2011

Conditions

Keywords

End stage Renal DiseaseHemodialysisOxidative StressInflammation

Outcome Measures

Primary Outcomes (1)

  • Net change in intracellular oxidative stress and intracellular proinflammatory cytokines levels

    The net change in the levels of intracellular IL-6, IL-6 soluble receptor, IL-6 gp130, superoxide, H2O2 and IL-1 during dialysis (difference between pre and post dialysis) using the new venous needle will be compared with the change using the current venous needle.

    4 hours of hemodialysis

Secondary Outcomes (1)

  • Net change in oxidative stress and proinflammatory cytokines in plasma

    4 hours hemodialysis

Study Arms (2)

New venous needle, the "BME needle"

EXPERIMENTAL

Hemodialysis using the new venous needle, the "BME needle".

Procedure: Hemodialysis using a new venous needle, the "BME needle"

Standard venous needle, the "standard needle"

ACTIVE COMPARATOR

One hemodialysis using the standard venous needle, the "standard needle" (device).

Procedure: Hemodialysis using the standard venous needle

Interventions

Hemodialysis using the standard venous dialysis needle

Also known as: hemodialysis using the standard venous dialysis needle
Standard venous needle, the "standard needle"

Hemodialysis using a new venous dialysis needle or the "BME needle"

Also known as: The "BME needle" is a newly designed venous dialysis needle.
New venous needle, the "BME needle"

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

DaVita K Street Dialysis Center

Washington D.C., District of Columbia, 20037, United States

RECRUITING

MeSH Terms

Conditions

Kidney Failure, ChronicInflammation

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Alfredo R Zarate, MD

    Biomedical Enterprises Inc

    PRINCIPAL INVESTIGATOR
  • Pedro A Jose, MD, PhD

    Children National Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pedro A Jose, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 9, 2011

First Posted

August 15, 2011

Study Start

August 1, 2011

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

August 15, 2011

Record last verified: 2011-08

Locations